Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 262 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder of Endocrine Ovary Clear all
Completed Not applicable Interventional

Stress Reduction for Overweight or Obese Women Either With Polycystic Ovary Syndrome (PCOS) or Without PCOS (Non-PCOS)

NCT01464398
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Overweight, Obesity, Stress, Physiological, Stress, Psychological
Interventions
Stress reduction, Stress reduction with Health education
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Early Phase 1 Interventional Results available

Fermented Wheat Germ Extract in Women With Ovarian Cancer

NCT02411565
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Fermented Wheat Germ Extract (FWGE), Placebo, Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

NCT00704912
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

NCT03030287
View directory record Official record
Conditions
Cancer Ovaries, Cancer Peritoneal, Cancer, Fallopian Tube
Interventions
OMP-305B83, Paclitaxel
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Aurora, Colorado • Tampa, Florida • Charlotte, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Results available

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

NCT00805935
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Infertility
Interventions
Menotropin, Progesterone vaginal insert, Follitropin beta, Progesterone in oil, leuprolide acetate
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Littleton, Colorado • Clearwater, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2012 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

NCT01428245
View directory record Official record
Conditions
Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Progesterone, Estrace (estrogen)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
8 Years to 14 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 22, 2026, 5:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions
A2B694, A2B543, xT CDx with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous Versus Cyclical OCP Use in PCOS

NCT03819140
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Yasmin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Not applicable Interventional

Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)

NCT02190097
View directory record Official record
Conditions
Polycystic Ovarian Syndrome
Interventions
Paleolithic diet, American Diabetes Association diet
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 22, 2026, 5:19 AM EDT
Recruiting No phase listed Observational

Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy

NCT04948658
View directory record Official record
Conditions
Turner Syndrome, Post-menarcheal Adolescents, Ovarian Disfunction, Galactosemia, Variations in Sex Characteristics, Differences in Sex Development
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 35 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 5:19 AM EDT
Not listed Phase 1Phase 2 Interventional

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

NCT00057395
View directory record Official record
Conditions
Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Neoplasms
Interventions
Aroplatin (Liposomal NDDP, L-NDDP)
Drug
Lead sponsor
Aronex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 5:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents

NCT01840618
View directory record Official record
Conditions
Obstructive Sleep Apnea Syndrome, Polycystic Ovary Syndrome, Sleep Apnea
Interventions
Nasal Continuous positive airway pressure (CPAP)
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

NCT05538624
View directory record Official record
Conditions
Neoplasm, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenocarcinoma Ovary, Serous Adenocarcinoma of Ovary, Serous Adenocarcinoma of Primary Peritoneum, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma
Interventions
AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase)
Drug
Lead sponsor
Avenge Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Bethesda, Maryland • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 2 Interventional

Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum

NCT00012090
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
bicalutamide, goserelin acetate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 22, 2026, 5:19 AM EDT
Completed No phase listed Observational

Adrenal Hyperplasia Among Young People With PCOS

NCT01313455
View directory record Official record
Conditions
Adrenal Hyperplasia, Polycystic Ovarian Syndrome, Oligomenorrhea, Obesity, Hyperandrogenism
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
16 Years to 29 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Phase 1 Interventional

Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

NCT00970541
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Insulin Resistance
Interventions
Cinnamon Supplementation, Placebo (wheat flour)
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 22, 2026, 5:19 AM EDT
Recruiting Not applicable Interventional

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

NCT05429970
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Carcinoma, Stage II Ovary Cancer, Stage II Ovarian Cancer, Stage III Ovary Cancer, Stage III Ovarian Cancer, Stage IV Ovary Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Stage II Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Mind-body resilience training, Music therapy, Propranolol, Etodolac
Behavioral · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional Results available

Optimal Timing of BR55 CEUS of the Ovaries

NCT04248153
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BR55
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 22, 2026, 5:19 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

NCT03281681
View directory record Official record
Conditions
Ovarian Cancer
Interventions
VAL-083, Dianhydrogalactitol
Drug
Lead sponsor
DelMar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Detroit, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 22, 2026, 5:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The PCOS Challenge Study

NCT05797909
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
PCOS Challenge: The National Polycystic Ovary Syndrome Association
Other
Eligibility
12 Years to 80 Years · Female only
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2042
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 22, 2026, 5:19 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Plant Exosomes and Patients Diagnosed With Polycystic Ovary Syndrome (PCOS) 17

NCT03493984
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Ginger exosomes, Aloe exosomes, Placebo
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 22, 2026, 5:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS

NCT01815138
View directory record Official record
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
hCG
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 22, 2026, 5:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

NCT03287271
View directory record Official record
Conditions
Ovarian Cancer
Interventions
VS-6063, Paclitaxel, Carboplatin
Drug
Lead sponsor
Michael McHale
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 5:19 AM EDT